The global monoclonal
antibodies (mAbs) market was valued at USD 85.4 billion in 2015
and is expected to reach a value of USD 138.6 billion by 2024. Increasing
R&D pertaining to the development of therapeutic mAbs coupled with
supportive government initiatives is expected to drive the monoclonal
antibodies market growth over the forecast period.
Increasing demand for personalized medicine is a vital
factor responsible for the increasing development of therapeutic antibodies to
provide targeted therapies as every individual responds in a different manner
to a particular treatment. Moreover, related benefits of using mAbs for
therapeutic purposes, including fewer adverse effects, homogeneity,
specificity, and large-scale production, are contributing toward significant market
growth.
In addition, the government initiatives to enable
cost-effective production of mAbs is anticipated to propel the emergence of
this sector over the forecast period. For instance, the biomanufacturing
initiative byNational Institute of Standards and Technology in the U.S.
provides scientifically sound regulatory guidelines to ensure effective and
safe manufacturing of protein therapeutics and to support biopharmaceutical
manufacturers in offering low-cost and high-quality protein drugs across the
globe.
Browse full research report on Monoclonal Antibodies (mAbs) Market: https://www.grandviewresearch.com/industry-analysis/monoclonal-antibodies-market
Further
Key Findings from the Study Suggest:
- Human-based mAbs segment is predicted to grow at a lucrative CAGR
in the coming years due to their associated benefits and numerous R&D
activities conducted for further development of human mAbs. Large number
of mAbs of human origin are in phase III clinical trial for cancer
treatment
- In vitro production of mAbs is anticipated to show the fastest
growth owing to its wide-scale adoption by biologics manufacturers due to
its greater efficiency in cost and time
- The research institute segment is anticipated to exhibit profitable
growth due to increasing R&D efforts in the biotech industry as
monoclonal antibodies have emerged as a major class of therapeutics for
several human diseases, particularly immunological infectious diseases and
cancer
- The Asia pacific region has significant growth potential due to
rising government initiatives in this region supporting the use of mAbs
for research and treatment purposes coupled with the surge in sponsored
R&D projects for the development of cost-effective therapeutic mAbs.
- For instance, government-led fund providers, such as National
Natural Science Foundation and National Basic Research Program of
China, offer financial support to enterprises and universities to conduct
mAb research and development.
- The key players serving the monoclonal antibodies market arePfizer,
Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc, Amgen, Inc.,
Abbott Laboratories, AstraZeneca, Eli Lilly and Company, Mylan N.V.,
Daiichi Sankyo Company, Ltd., Bayer AG, Bristol Myers Squibb Co.,Johnson
& Johnson Services, Inc., Biogen Inc., Thermo Fisher Scientific, Inc.,
Sanofi Genzyme, F. Hoffmann-La Roche Ltd., and Novo Nordisk A/S.
- The introduction of advanced methods for mAb production further
encourages the pharmaceutical companies to build their own product
pipeline. According to a study published by NCBI at the end of 2013,
approximately 816 companies were involved in therapeutic protein
research.
Browse more reports of this category
by Grand View Research: https://www.grandviewresearch.com/industry/biotechnology
Grand
View Research has segmented the monoclonal antibodies market by source type,
production, indication, end-use, and region:
Global Monoclonal
Antibodies Source Type Outlook (Revenue, USD Billion, 2013 - 2024)
- Murine
- Chimeric
- Humanized
- Human
Global Monoclonal
Antibodies Production Type Outlook (Revenue, USD Billion, 2013 - 2024)
- In Vivo
- In Vitro
Global Monoclonal
Antibodies Indication Outlook (Revenue, USD Billion, 2013 - 2024)
- Cancer
- Autoimmune
Diseases
- Inflammatory
Diseases
- Infectious
Diseases
- Microbial
Diseases
- Others
Global Monoclonal
Antibodies End-use Outlook (Revenue, USD Billion, 2013 - 2024)
- Hospitals
- Research
Institutes
- Others
Monoclonal
antibodies Market Regional Outlook (Market Revenue in USD Billion,
2013 - 2024)
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- Asia Pacific
- Japan
- China
- India
- Latin America
- Brazil
- Mexico
- Middle East
and Africa
- South Africa
About Grand View
Research
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
No comments:
Post a Comment